The effect of Treatment of sleep disorders on cognitive function, quality of life and CD4 + counts in people with HIV+ / AIDS

The effect and no effect of Treatment of sleep disorders on cognitive function, quality of life and CD4 + counts in people with HIV+ / AIDS

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016110923705N8

Enrollment

Registered

2016-11-27

Start date

2016-11-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV+/AIDS. Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases

Interventions

Intervention 1: In the experimental group 2, the participant will receive Sleep hygiene education(2 hours weekly). then questionnaire will be redistributed at baseline,4 weeks later, and at the end of

And the quality of life, cognitive function, CD4 + count will be measured. Intervention 2: In the experimental group 1, the participant will receive trazodone drug 25 mg to 100mg daily. then question

And the quality of life, cognitive function, CD4 + count will be measured. Intervention 3: In the experimental group 3, the participant will be undertreated by a combination of treatment with trazodo

And the quality of life, cognitive function, CD4 + count will be measured.

Behavior

Treatment - Drugs

In the experimental group 2, the participant will receive Sleep hygiene education(2 hours weekly). then questionnaire will be redistributed at baseline,4 weeks later, and at the end of the study (8 we

And the quality of life, cognitive function, CD4 + count will be measured

In the experimental group 1, the participant will receive trazodone drug 25 mg to 100mg daily. then questionnaire will be redistributed at baseline,4 weeks later, and at the end of the study (8 weeks

In the experimental group 3, the participant will be undertreated by a combination of treatment with trazodone and sleep hygiene education ). then questionnaire will be redistributed at baseline,4 w

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Having a sleep disorder; Patients treated with methadone; Having HIV+ / AIDS; Diagnose of sleep disorders by a psychiatrist that are not treated for sleep disorders. Exclusion criteria: Use of any drug or medication that impairs sleep; any other psychiatric and physical illness

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Cognitive function. Timepoint: The beginning of the study (baseline), week four and end of the study (week eight). Method of measurement: StroopTest.;Quality of life. Timepoint: The beginning of the study (baseline), week four and end of the study (week eight). Method of measurement: World health organization quality of life brief Scale.;CD4+. Timepoint: The beginning of the study (baseline), week four and end of the study (week eight). Method of measurement: By Flow cytometry.	—

Measure

Time frame

Cognitive function. Timepoint: The beginning of the study (baseline), week four and end of the study (week eight). Method of measurement: StroopTest.;Quality of life. Timepoint: The beginning of the study (baseline), week four and end of the study (week eight). Method of measurement: World health organization quality of life brief Scale.;CD4+. Timepoint: The beginning of the study (baseline), week four and end of the study (week eight). Method of measurement: By Flow cytometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Habib Allah Khazaie

Kermanshah University of Medical Sciences

ha_khazaie@yahoo.com+98 83 3826 0700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026